SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Andrew H who wrote (14971)2/13/1998 8:08:00 AM
From: tonyt  Read Replies (1) | Respond to of 32384
 
> new leptin deal

Are you implying that there is an existing leptin deal?
I thought that we were still waiting for the first leptin deal.



To: Andrew H who wrote (14971)2/13/1998 8:29:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Andy, I never ceases to amaze me how some posters can put up dozens of posts and still know virtually nothing about the underlying stock. Of course there is a leptin deal. The leptin promoter program was folded into the LLY deal. It targets the promoter as a means of controlling leptin levels (through agonists as well as antagonists). LGND is currently working on the signaling leptin deal. That deal has been delayed forever, and Robinson had indicated that LGND would switch partners if not finalized by the end of last month. Bernie has indicated that a fall back position (new partner) was waiting in the wings and would take a relatively short time to finalize.



To: Andrew H who wrote (14971)2/13/1998 8:35:00 AM
From: Henry Niman  Read Replies (2) | Respond to of 32384
 
This is from the Oct 20 press release announcing the LLY deal:

"Finally, Lilly will receive exclusive rights to the HNF4 (hepatic
nuclear factor 4) receptor and the obesity gene promoter technology."

As most posters on the board know, the obesity gene is the leptin gene.